

REMARKS/ARGUMENTS

I. Status of Claims

Claims 1-32 were originally filed. Claims 1-32 were subject to a Restriction Requirement. After response to the Restriction Requirement, claims 1-2, 4-32 are elected for prosecution. Claims 1 and 2 are amended to correct typographical and punctuation mistakes. Claim 2 is amended to insert an -OH group for R₁, R₂, R₃ and R₄. Support for this amendment, for example, may be found in compounds 127 and 131. Claims 1, 2, 19, 21, 26, 27 and 29-32 are amended to recite proper Markush groups. Claim 28 is amended to correct punctuation mistakes and change claim dependency. Claim 28 is also amended to recite a proper Markush group. Claims 29-32 are amended to make the claims clear and concise. New claims 33-39 are added. New claims 33-39 are directed to particular species of Formula II and are readable on the elected species. No new matter has been added. Support for the new claims may be found throughout the specification.


II. Response to the Restriction Requirement

The claims are restricted into two groups. Applicants elect Group II for prosecution on the merits. The claims of Group II are drawn an Edg-2 receptor antagonist represented by the instant formula. Claims 1-2 and 4-32 fall within Group II. New claims 33-39 also fall within Group II.

The election of the claims of Group II is made with traverse. The claims emerge from a common inventive concept; an Edg-2 receptor agonist represented by the instant formula and an Edg-2 receptor antagonist represented by the instant formula. The Applicants respectfully submit that searching the Edg-2 receptor agonist represented by the instant formula and the Edg-2 receptor antagonist represented by the instant formula would not be an undue burden on the Examiner.

III. Response to the Election of Species Requirement

The Examiner has required the Applicants to elect a single species and a disease condition in which the identity of each claim element is explicitly set forth. Applicants' elect compound 131 which is set forth below:



Applicants elect cancer as the disease condition. Cancer includes but is not limited to ovarian cancer, peritoneal cancer, endometrial cancer, cervical cancer, breast cancer, colorectal cancer, uterine cancer, stomach cancer, small intestine cancer, thyroid cancer, lung cancer, kidney cancer, pancreas cancer and prostate cancer. Applicants submit that pending claims 1-2 and 4-32 and new claims 33-39 are readable on the elected species.

Applicants respectfully submit that such elections are without prejudice and expressly reserve the right to prosecute the non-elected species and claims at a later stage.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

Appl. No. 10/760,063
Amdt. dated October 24, 2006
Office Action dated April 25, 2006

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-442-1000.

Respectfully submitted,



Alok Goel (Reg. No. 51,745) on behalf of
Thomas D. Kohler (Reg. No. 32,797)

MORGAN, LEWIS & BOCKIUS, LLP
Two Palo Alto Square
3000 El Camino Real, Ste. 700
Palo Alto, CA 94306
Tel. (415) 442-1000
Direct Dial: (415) 442-1433
eFAX: (650) 843-4001
e-mail: agoel@morganlewis.com